Evidence map›Paper›PMID 37667182›Full record

Observational studyBMC infectious diseases2023

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.

Inès Devred, Kick Kayembe, Nadia Valin, Hayette Rougier, Bruce Wuembulua Shinga, Sidonie Lambert-Niclot, Thibault Chiarabini, Marie-Caroline Meyohas, Karine Lacombe

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Inès DevredHôpital Saint-Antoine, Assistance Publique Des Hôpitaux de Paris, Service Des Maladies Infectieuses Et Tropicales, 184 Rue du Faubourg Saint-Antoine, F75571, Cedex 12, Paris, France. inesdevred@hotmail.com.
Kick KayembeHôpital Saint-Antoine, Assistance Publique Des Hôpitaux de Paris, Service Des Maladies Infectieuses Et Tropicales, 184 Rue du Faubourg Saint-Antoine, F75571, Cedex 12, Paris, France. kickkayembe@gmail.com.
Nadia ValinHôpital Saint-Antoine, Assistance Publique Des Hôpitaux de Paris, Service Des Maladies Infectieuses Et Tropicales, 184 Rue du Faubourg Saint-Antoine, F75571, Cedex 12, Paris, France.
Hayette RougierHôpital Saint-Antoine, Assistance Publique Des Hôpitaux de Paris, Service Des Maladies Infectieuses Et Tropicales, 184 Rue du Faubourg Saint-Antoine, F75571, Cedex 12, Paris, France.
Bruce Wuembulua ShingaHôpital Saint-Antoine, Assistance Publique Des Hôpitaux de Paris, Service Des Maladies Infectieuses Et Tropicales, 184 Rue du Faubourg Saint-Antoine, F75571, Cedex 12, Paris, France.
Sidonie Lambert-NiclotSorbonne Université, 91-105 Boulevard de L'Hôpital, 75013, Paris, France.
Thibault ChiarabiniHôpital Saint-Antoine, Assistance Publique Des Hôpitaux de Paris, Service Des Maladies Infectieuses Et Tropicales, 184 Rue du Faubourg Saint-Antoine, F75571, Cedex 12, Paris, France.
Marie-Caroline MeyohasHôpital Saint-Antoine, Assistance Publique Des Hôpitaux de Paris, Service Des Maladies Infectieuses Et Tropicales, 184 Rue du Faubourg Saint-Antoine, F75571, Cedex 12, Paris, France.
Karine LacombeHôpital Saint-Antoine, Assistance Publique Des Hôpitaux de Paris, Service Des Maladies Infectieuses Et Tropicales, 184 Rue du Faubourg Saint-Antoine, F75571, Cedex 12, Paris, France.
Sorbonne Université · FRHôpital Saint-Antoine · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV post- exposure prophylaxis (PEP) is a prevention tool for individuals with a recent potential exposure to HIV. Doravirine has been available since 2019 in combination with tenofovir disoproxil fumarate and lamivudine and has not been evaluated as a PEP. DOR/3TC/TDF is our department's most commonly prescribed PEP treatment since 2021. This study evaluates the completion rate of the DOR/3TC/TDF as compared to EVG/c/FTC/TAF for PEP, which was the regimen prescribed until 2020 in our hospital.This retrospective observational study was conducted between January 2020 and September 2021. The subjects included consecutively were adults who consulted for an HIV sexual exposure accident and for whom DOR/3TC/TDF in 2021 or EVG/c/FTC/TAF in 2020 was prescribed. The outcomes were the completion rate to the end of treatment (28 days), the seroconversion rate, and the description of side effects.During the study period, 311 people were included: 140 treated with DOR/3TC/TDF and 171 treated with EVGc/FTC/TAF. Considering subjects with a follow-up visit, the completion rate was 96.8% (90/93) in the DOR/3TC/TDF group, and 94.6% (123/130) in the EVG/c/FTC/TAF group (p-value: 0.53). The number of people lost to follow-up was nearly equivalent in both groups: 27.1% (38/140) in the DOR/3TC/TDF group and 23.4% (40/171) in the EVG/c/FTC/TAF group (p-value: 0.45). A side effect was described for 38% (36/94) in the DOR/3TC/TDF group, and 29.7% (38/128) in the EVG/c/FTC/TAF group. No cases of seroconversion were observed.DOR/3TC/TDF appears to have a similar safety profile to EVG/c/FTC/TAF. Due to its lower cost, it seems to be a treatment option for consideration in the context of HIV-exposure accidents.

Indexed as

Anti-HIV AgentsDrug-Related Side Effects and Adverse ReactionsHIV InfectionsAdultAlanineCobicistatEmtricitabineFumaratesHumansLamivudinePyridonesQuinolonesTenofovirTriazolesAlanineAnti-HIV AgentsCobicistatdoravirineelvitegravirEmtricitabineFumaratesLamivudinePyridonesQuinolonesTenofovirtenofovir alafenamideTriazolesAdherenceCompletion rateDoravirineHIVPost-exposure prophylaxis

Identifiers

PMID37667182
PMCPMC10478445
OpenAlexW4386423097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.